Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
3(43%)
Results Posted
100%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
1
14%
Ph not_applicable
1
14%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 31 (14.3%)
N/A1 (14.3%)

Trials by Status

completed343%
terminated114%
active_not_recruiting229%
recruiting114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_1

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
active_not_recruitingphase_2

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163
terminatedphase_3

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
active_not_recruitingphase_1

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT04179162
completednot_applicable

Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity

NCT03246230
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03317158Phase 1

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Recruiting
NCT03504163Phase 2

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Active Not Recruiting
NCT04149574Phase 3

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Terminated
NCT04179162Phase 1

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Active Not Recruiting
NCT03246230Not Applicable

Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity

Completed
NCT02281383Phase 2

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Completed
NCT02075203Phase 2

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7